Children on Losing End of Access to New Drugs

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Children on Losing End of Access to New Drugs

AIDS Alert (01/98) Vol. 13, No. 1, P. 10

Abstract: In response to the finding that only five of 14 approved AIDS drugs have been tested in children and no protease inhibitors have been approved for pediatric patients under age two, the White House has proposed a rule to require pharmaceutical companies to test more drugs in children and report data to the Food and Drug Administration at the same time, or shortly after, the drug is okayed for adults. The Better Pharmaceuticals for Children Act, part of recent FDA reform legislation, supports that rule by setting up marketing incentives for pharmaceutical companies to encourage the testing of drugs in children. However, the AIDS Policy Center and other children's groups fear the rule has too many waivers, giving manufacturers numerous loopholes. To address many of the concerns about pediatric HIV drugs, the International Association for Physicians in AIDS Care has launched "Children First," a demonstration project in several states that will work to create resources and structures to provide all HIV-positive children with access to all HIV drugs within three years. The group has organized a 1998 meeting of drug companies, clinicians, and government health officials to set an agenda for pediatric HIV treatment research and make plans to develop a pediatric HIV mentor program. IAPAC will also develop a pediatric HIV resource center and suggests appointing a national pediatric HIV drug coordinator.

971224
AD972347

Copyright © 1997 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.